Lisa Bloudek
Overview
Explore the profile of Lisa Bloudek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
82
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Velez F, Rajani R, Malone D, Sun L, Sun L, Bloudek L, et al.
J Med Econ
. 2025 Feb;
28(1):323-334.
PMID: 39964834
Aims: To predict the budget impact of Symvess (Symvess is a trademark of Humacyte Global, Inc.) (acellular tissue engineered vessel-tyod [ATEV]) for extremity arterial trauma repair when autologous vein repair...
2.
Esquenazi A, Bloudek L, Migliaccio-Walle K, Oliveri D, Tung A, Gillard P, et al.
J Rehabil Med
. 2023 Oct;
55:jrm11626.
PMID: 37902443
Background: Real-world data regarding the impact of onabotulinumtoxinA on healthcare resource utilization and costs for post-stroke spasticity are scarce. Objective: To compare differences in 12-month healthcare resource utilization and costs...
3.
Singh H, Kang A, Bloudek L, Hsu L, Corinna Palanca-Wessels M, Stecher M, et al.
JNCI Cancer Spectr
. 2023 Oct;
8(1).
PMID: 37815820
Background: Colorectal cancer (CRC) is the second most common cause of cancer death globally. Recent clinical trials suggest an emerging role for HER2 as a potential clinically relevant biomarker in...
4.
Bloudek L, Wright P, McKay C, Derleth C, Lill J, Lenero E, et al.
Curr Oncol
. 2023 May;
30(4):3637-3647.
PMID: 37185390
To compare efficacy outcomes for all approved and investigational first-line (1L) treatment regimens for locally advanced or metastatic urothelial carcinoma (la/mUC) with standard of care (SOC), a network meta-analysis (NMA)...
5.
McIntyre R, Bloudek L, Timmons J, Gillard P, Harrington A
Curr Med Res Opin
. 2023 Feb;
39(4):605-611.
PMID: 36776128
Introduction: Misdiagnosis of bipolar I disorder (BP-I) as major depressive disorder (MDD) leads to increased healthcare resource utilization and costs. The cost-effectiveness of the Rapid Mood Screener (RMS), a tool...
6.
Yeung K, Bloudek L, Ding Y, Sullivan S
JAMA Health Forum
. 2022 Dec;
3(12):e224631.
PMID: 36484998
No abstract available.
7.
Bloudek B, Wirtz H, Hepp Z, Timmons J, Bloudek L, McKay C, et al.
Clin Epidemiol
. 2022 Nov;
14:1375-1386.
PMID: 36404878
Objective: We demonstrate a new model framework as an innovative approach to more accurately estimate and project prevalence and survival outcomes in oncology. Methods: We developed an oncology simulation model...
8.
Bloudek L, Eichenfield L, Silverberg J, Joish V, Lofland J, Sun K, et al.
Am J Clin Dermatol
. 2022 Oct;
24(1):109-117.
PMID: 36264430
Background: Atopic dermatitis is a chronic inflammatory skin disease that can negatively impact work productivity and daily activities. Ruxolitinib cream, a Janus kinase inhibitor, demonstrated efficacy and safety in patients...
9.
Jaksa A, Bloudek L, Carlson J, Shah K, Chen Y, Patrick A, et al.
Int J Technol Assess Health Care
. 2022 Mar;
38(1):e32.
PMID: 35357284
Health technology assessment (HTA) agencies are considering adopting a lifecycle approach to assessments to address uncertainties in the evidence base at launch and to revisit the clinical and economic value...
10.
Musa F, Brouwer E, Ting J, Schwartz N, Surinach A, Bloudek L, et al.
Gynecol Oncol
. 2022 Jan;
164(3):645-650.
PMID: 35031189
Background: Current treatments for recurrent or metastatic cervical cancer (r/mCC) do not offer satisfactory clinical benefits, with most patients progressing beyond first-line (1L) treatment. With new treatments under investigation, understanding...